China Shineway Pharmaceutical Group (HKSE:02877) Net Income From Continuing Operations : HK$1,060 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is China Shineway Pharmaceutical Group Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. China Shineway Pharmaceutical Group's net income from continuing operations for the six months ended in Dec. 2023 was HK$523 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,060 Mil.

China Shineway Pharmaceutical Group Net Income From Continuing Operations Historical Data

The historical data trend for China Shineway Pharmaceutical Group's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Shineway Pharmaceutical Group Net Income From Continuing Operations Chart

China Shineway Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

715.25

468.27

881.74

1,024.06

1,356.56

China Shineway Pharmaceutical Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															303.94	388.14	437.36	537.56	522.88

China Shineway Pharmaceutical Group Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,060 Mil.

China Shineway Pharmaceutical Group (HKSE:02877) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Shineway Pharmaceutical Group Ltd (HKSE:02877) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

C1S:Germany

Address

Luan Cheng, Hebei Province, Shijiazhuang, CHN

Website

http://www.shineway.com.hk

China Shineway Pharmaceutical Group Ltd is an investment holding company in the People's Republic of China. Principally, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, and others of which injection generates maximum revenue to the company.

Executives

Bh Corporate Services Ltd	2301 Trustee
Bodnar-horvath Kwai Yung Helen	2202 Interest of your spouse
Bodnar-horvath Nicholas Eugene Francis	2201 Interest of corporation controlled by you
Forway Investment Limited	2101 Beneficial owner
Li Zhenjiang	2307 Founder of a discretionary trust who can infl

China Shineway Pharmaceutical Group (HKSE:02877) Headlines

No Headlines